Cargando…

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro

BACKGROUND: Human papillomavirus- (HPV-) associated oropharyngeal squamous cell carcinomas (OPSCCs) are clinically and pathologically distinct from HPV-negative tumors. Here, we explore whether HPV affects functional biomarkers, including γH2AX, RAD51, and PARP1. Moreover, the role of [(18)F]PARPi a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guru, Navjot, Demétrio De Souza França, Paula, Pirovano, Giacomo, Huang, Cien, Patel, Snehal G., Reiner, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205605/ https://www.ncbi.nlm.nih.gov/pubmed/34194286 http://dx.doi.org/10.1155/2021/6641397

Ejemplares similares

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

Fluorescence-guided resection of tumors in mouse models of oral cancer
por: Demétrio de Souza França, Paula, et al.
Publicado: (2020)

Fluorescence labeling of a Na(V)1.7-targeted peptide for near-infrared nerve visualization
por: Gonzales, Junior, et al.
Publicado: (2020)

Discriminating radiation injury from recurrent tumor with [(18)F]PARPi and amino acid PET in mouse models
por: Donabedian, Patrick L., et al.
Publicado: (2018)

Two experts and a newbie: [(18)F]PARPi vs [(18)F]FTT vs [(18)F]FPyPARP—a comparison of PARP imaging agents
por: Stotz, Sophie, et al.
Publicado: (2021)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

Correction: Pacelli et al. Fully Automated, High-Dose Radiosynthesis of [18F]PARPi. Pharmaceuticals 2022, 15, 865
por: Pacelli, Anna, et al.
Publicado: (2023)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

Low E2F2 activity is associated with high genomic instability and PARPi resistance
por: Rennhack, Jonathan P., et al.
Publicado: (2020)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Preclinical and first-in-human-brain-cancer applications of [(18)F]poly (ADP-ribose) polymerase inhibitor PET/MR
por: Young, Robert J, et al.
Publicado: (2020)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
por: Di Raimo, Tania, et al.
Publicado: (2020)

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
por: O’Sullivan, Julia, et al.
Publicado: (2023)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment
por: Mori, Federica, et al.
Publicado: (2013)

PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Ambur Sankaranarayanan, Ramya, et al.
Publicado: (2022)

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes
por: Todisco, Elisabetta, et al.
Publicado: (2022)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients
por: Li, Lei, et al.
Publicado: (2023)

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
por: Sun, Chenggong, et al.
Publicado: (2020)

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
por: Vos, Janet R, et al.
Publicado: (2019)

Correction: PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2023)

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway
por: Cao, Qi, et al.
Publicado: (2023)

The Aqueous Extract of Ficus religiosa Induces Cell Cycle Arrest in Human Cervical Cancer Cell Lines SiHa (HPV-16 Positive) and Apoptosis in HeLa (HPV-18 Positive)
por: Choudhari, Amit S., et al.
Publicado: (2013)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
por: Rose, Peter G.
Publicado: (2022)

Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers
por: Kossatz, Susanne, et al.
Publicado: (2020)

Acute saddle pulmonary embolism on (18)F‐FDG PET/CT: diagnosis by functional imaging
por: Singh, Dalveer, et al.
Publicado: (2019)

Prevalence of HPV 16 and HPV 18 Lineages in Galicia, Spain
por: Pérez, Sonia, et al.
Publicado: (2014)

Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70
por: Chen, Zigui, et al.
Publicado: (2013)

Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence
por: Arbyn, Marc, et al.
Publicado: (2020)

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
por: Stemmer, Amos, et al.
Publicado: (2020)

The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC)
por: Rose, Peter G, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtuq3bpndos4q1ae59r3dpli4c